Ito K - Search Results

1

The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.

Hirama H, Sugimoto M, Ito K, Shiraishi T, Kakehi Y. Hirama H, et al. Among authors: ito k. J Cancer Res Clin Oncol. 2014 Feb;140(2):257-63. doi: 10.1007/s00432-013-1566-2. Epub 2013 Dec 19. J Cancer Res Clin Oncol. 2014. PMID: 24352745 Free PMC article.

2

Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities.

Kubota Y, Ito K, Imai K, Yamanaka H. Kubota Y, et al. Among authors: ito k. Prostate. 2002 Mar 1;50(4):262-9. doi: 10.1002/pros.10057. Prostate. 2002. PMID: 11870805

3

Usefulness of prostate-specific antigen velocity in screening for prostate cancer.

Ito K, Yamamoto T, Ohi M, Kubota Y, Fukabori Y, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Int J Urol. 2002 Jun;9(6):316-21. doi: 10.1046/j.1442-2042.2002.00466.x. Int J Urol. 2002. PMID: 12110095 Free article.

4

The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL.

Ito K, Ohi M, Yamamoto T, Miyamoto S, Kurokawa K, Fukabori Y, Suzuki K, Yamanaka H. Ito K, et al. Cancer. 2002 Nov 15;95(10):2112-9. doi: 10.1002/cncr.10941. Cancer. 2002. PMID: 12412164 Free article.

5

Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes?

Kurokawa K, Ito K, Suzuki K, Ono Y, Yamamoto T, Akimoto T, Yamanaka H. Kurokawa K, et al. Among authors: ito k. Jpn J Clin Oncol. 2002 Nov;32(11):466-71. doi: 10.1093/jjco/hyf096. Jpn J Clin Oncol. 2002. PMID: 12499419

6

Natural history of PSA increase with and without prostate cancer.

Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Urology. 2003 Jul;62(1):64-9. doi: 10.1016/s0090-4295(03)00135-3. Urology. 2003. PMID: 12837424

7

Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.

Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Prostate. 2003 Sep 15;57(1):8-13. doi: 10.1002/pros.10268. Prostate. 2003. PMID: 12886518

8

Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.

Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, Nishii M, Ohtake N, Nakata S, Ito K, Yamanaka H. Suzuki K, et al. Among authors: ito k. Cancer. 2003 Oct 1;98(7):1411-6. doi: 10.1002/cncr.11639. Cancer. 2003. PMID: 14508827 Free article.

9

Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4ng/ml.

Ohi M, Ito K, Suzuki K, Yamamoto T, Yamanaka H. Ohi M, et al. Among authors: ito k. Eur Urol. 2004 Jan;45(1):92-6; discussion 96-7. doi: 10.1016/j.eururo.2003.07.001. Eur Urol. 2004. PMID: 14667523

10

The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less.

Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H. Ito K, et al. J Urol. 2004 Feb;171(2 Pt 1):656-60. doi: 10.1097/01.ju.0000100109.23348.6b. J Urol. 2004. PMID: 14713780

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12,108 results

Search Page

Filters